CSIMarket



Bristol myers Squibb Company  (BMY)
Other Ticker:  
 
 

BMY's Capital Expenditures Growth by Quarter and Year

Bristol Myers Squibb's Capital Expenditures results by quarter and year




BMY Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 320.00 283.00 251.00
III Quarter September - 270.00 153.00 190.00
II Quarter June - 210.00 131.00 191.00
I Quarter March 253.00 173.00 186.00 204.00
FY   253.00 973.00 753.00 836.00



BMY Capital Expenditures first quarter 2022 Y/Y Growth Comment
Bristol myers Squibb Company achieved in the first quarter 2022, above Company average Capital Expenditures rise of 46.24% year on year, to $ 253.00 millions.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Capital Expenditures growth. While Bristol Myers Squibb Company' s Capital Expenditures jump of 46.24% ranks overall at the positon no. 698 in the first quarter 2022.




BMY Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 13.07 % 12.75 % -13.45 %
III Quarter September - 76.47 % -19.47 % -15.18 %
II Quarter June - 60.31 % -31.41 % -3.54 %
I Quarter March 46.24 % -6.99 % -8.82 % -14.64 %
FY   - 29.22 % -9.93 % -12.09 %

Financial Statements
Bristol Myers Squibb's first quarter 2022 Capital Expenditures $ 253.00 millions BMY's Income Statement
Bristol Myers Squibb's first quarter 2021 Capital Expenditures $ 173.00 millions Quarterly BMY's Income Statement
New: More BMY's historic Capital Expenditures Growth >>


BMY Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 18.52 % 84.97 % 32.11 %
III Quarter September - 28.57 % 16.79 % -0.52 %
II Quarter June - 21.39 % -29.57 % -6.37 %
I Quarter March -20.94 % -38.87 % -25.9 % -29.66 %
FY (Year on Year)   - 29.22 % -9.93 % -12.09 %




Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #89
Overall #698

Capital Expenditures Y/Y Growth Statistics
High Average Low
1193.98 % 26.81 % -22.37 %
(Dec. 31, 2009)   (Dec. 31, 2010)
Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #89
Overall #698
Capital Expenditures Y/Y Growth Statistics
High Average Low
1193.98 % 26.81 % -22.37 %
(Dec. 31, 2009)   (Dec. 31, 2010)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Bristol Myers Squibb's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
98.67 % 8.62 % -100 %
(June 30. 2011)  


BMY's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2022 Bristol Myers Squibb Company disclosed fall in Capital Expenditures from the previous quarter by -20.94% to $ 253.00 millions, from $ 320.00 millions achived in the previous quarter.

When you analyse present downturn in the I. Quarter 2022, you must take into consideration, that commonly I. Quarter 2022 results occur weaker then in the forth quarter

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Bristol Myers Squibb's Capital Expenditures growth quarter on quarter, overall rank is 1015.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #134
Overall #1015
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #134
Overall #1015
Capital Expenditures Q/Q Growth Statistics
High Average Low
98.67 % 8.62 % -100 %
(June 30. 2011)  


BMY's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2022 Bristol Myers Squibb Company reported fall in Capital Expenditures from the forth quarter by -20.94% to $ 253.00 millions, from $ 320.00 millions released in the previous quarter.

If you evaluate recent shortcoming at the I. Quarter, you must assume, that frequently I. Quarter 2022 results occur softer then in the quarter before, Colin Evans, Healthcare sector contributor allocated in San Francisco added.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Bristol Myers Squibb's Capital Expenditures growth quarter on quarter, overall rank is 1015.


Bristol Myers Squibb's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Capital Expenditures 12 Months Ending $ 1,053.00 $ 973.00 $ 936.00 $ 819.00 $ 740.00
Y / Y Capital Expenditures Growth (TTM) 42.3 % 29.22 % 29.82 % 8.05 % -9.54 %
Year on Year Capital Expenditures Growth Overall Ranking # 651 # 165 # 152 # 1160 # 1373
Seqeuential Capital Expenditures Change (TTM) 8.22 % 3.95 % 14.29 % 10.68 % -1.73 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 698 # 225 # 909 # 1150 # 1559




Cumulative Capital Expenditures growth Comment
Bristol Myers Squibb saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 42.3% year on year, to $ 1,053 millions if the fiscal year would have ended in Mar 31 2022.
Bristol Myers Squibb's trailing twelve months Capital Expenditures growth was higher than company's average 28.59% and higher than 29.22% growth in Dec 31 2021.
But from twelve months ended Dec 31 2021 growth rate was less at 8.22 % from $973 millions reported in twelve months ending a quarter before.
There is drop-off happening, more evident as we look at If you typical sequential historic rise which is stronger at26.81%.
The progress was much higher from the previous reporting period exhibited at 8.22 % increase from $973 millions in twelve months ending a quarter Dec 31 2021.

In the Healthcare sector 88 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 165 to 651.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1193.98 %
26.81 %
-22.37 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 89
Overall # 651

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
928.57 %
28.59 %
-39.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 89
S&P 500 # 698
Cumulative Capital Expenditures growth Comment
Bristol Myers Squibb saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 42.3% year on year, to $ 1,053 millions if the fiscal year would have ended in Mar 31 2022.
Bristol Myers Squibb's trailing twelve months Capital Expenditures growth was higher than company's average 28.59% and higher than 29.22% growth in Dec 31 2021.
But from the previous reporting period increase was less at 8.22 % from $973 millions recorded in the period from Dec 31 2021 to Mar 31 2021 Colin Evans added on.
There is slowdown happening, more evident observing the If you typical sequential Capital Expenditures rise that is stronger at26.81% Colin Evans noted.
The growth was even stronger from twelve months ended Dec 31 2021 clinched at 8.22 % rise from $973 millions in the period from Dec 31 2021 to Mar 31 2021.

In the Healthcare sector 88 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 165 to 651.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1193.98 %
26.81 %
-22.37 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 89
Overall # 651

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
928.57 %
28.59 %
-39.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 89
S&P 500 # 698




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
BMY's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for BMY's Competitors
Capital Expenditures Growth for Bristol Myers Squibb's Suppliers
Capital Expenditures Growth for BMY's Customers

You may also want to know
BMY's Annual Growth Rates BMY's Profitability Ratios BMY's Asset Turnover Ratio BMY's Dividend Growth
BMY's Roe BMY's Valuation Ratios BMY's Financial Strength Ratios BMY's Dividend Payout Ratio
BMY's Roa BMY's Inventory Turnover Ratio BMY's Growth Rates BMY's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2022
Resmed Inc 78.96%$ 78.963 millions
Ngm Biopharmaceuticals Inc 78.13%$ 78.125 millions
Agile Therapeutics Inc77.46%$ 77.465 millions
Alimera Sciences Inc 77.38%$ 77.381 millions
Surmodics Inc 76.61%$ 76.606 millions
Reneo Pharmaceuticals Inc 76.00%$ 76.000 millions
Actinium Pharmaceuticals Inc 75.00%$ 75.000 millions
Ocular Therapeutix Inc 74.68%$ 74.684 millions
Tivity Health Inc 73.93%$ 73.927 millions
Axogen inc 72.78%$ 72.778 millions
Clearpoint Neuro Inc 72.50%$ 72.500 millions
Vor Biopharma Inc 71.73%$ 71.734 millions
Option Care Health Inc 71.60%$ 71.598 millions
Nkarta Inc 71.35%$ 71.346 millions
Sotera Health Company69.74%$ 69.735 millions
Neurocrine Biosciences Inc 68.89%$ 68.889 millions
Aligos Therapeutics Inc 67.75%$ 67.752 millions
Organon and Co 65.79%$ 65.789 millions
Healthcare Services Group Inc 65.53%$ 65.529 millions
Owens and Minor Inc 65.50%$ 65.499 millions
Icu Medical Inc63.46%$ 63.457 millions
Athersys Inc63.16%$ 63.158 millions
Intuitive Surgical Inc 62.29%$ 62.287 millions
Avantor Inc 62.25%$ 62.252 millions
Axon Enterprise inc 62.23%$ 62.233 millions
Hims and Hers Health Inc 61.52%$ 61.519 millions
Boston Scientific Corporation61.33%$ 61.333 millions
Outset Medical Inc 60.83%$ 60.827 millions
Neuronetics Inc 59.11%$ 59.111 millions
Kura Oncology Inc 58.06%$ 58.065 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AMGC's Profile

Stock Price

AMGC's Financials

Business Description

Fundamentals

Charts & Quotes

AMGC's News

Suppliers

AMGC's Competitors

Customers & Markets

Economic Indicators

AMGC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071